NPI: 1770027294 · BROOKLYN, NY 11220 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 12/19/2016
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 12/19/2016 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,040 | $49K |
| 2019 | 8,994 | $168K |
| 2020 | 13,787 | $175K |
| 2021 | 14,488 | $332K |
| 2022 | 14,432 | $426K |
| 2023 | 10,911 | $595K |
| 2024 | 9,648 | $660K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 18,563 | 1,406 | $1.49M |
| A4657 | Syringe, with or without needle, each | 17,751 | 1,705 | $639K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 29,854 | 927 | $240K |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 1,282 | 409 | $20K |
| J1756 | Injection, iron sucrose, 1 mg | 409 | 99 | $11K |
| 82728 | 3,756 | 387 | $6K | |
| 82108 | 1,482 | 120 | $2K | |
| 83970 | 142 | 29 | $701.63 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 61 | 12 | $200.19 |